Biosimilar competition took a big chunk of revenue from Roche's aging blockbusters in 2020, and the company is banking on its newer medicines to drive fresh revenue growth.
Biosimilar competition took a $6.34 billion bite out of international revenues for Roche in 2020. It was the biggest decline so far attributable to biosimilar competition, according to Bill Anderson, CEO of Roche Pharmaceuticals. “I think we’ve seen the worst that it can get,” he said in an investor presentation. He anticipated a smaller-but-still-painful $5.1 billion biosimilar impact in 2021.
Roche faces accelerating biosimilar competition, particularly in the United States, for 3 of its aging blockbusters: Herceptin (trastuzumab), Avastin (bevacizumab), and Rituxan/MabThera (rituximab). For those products in just the United States, Japan, and European Union in 2020, biosimilar competition eroded $5.68 billion in revenue, Roche said.
The sales erosion for Roche is evidence of the power of biosimilars to capture market share despite the many barriers in the United States and internationally that prevent these drugs from challenging higher-priced originator products.
Biosimilar Blockbusters
A strong biosimilar portfolio can be the equivalent of a blockbuster product for a company with marketing power and reach. For example, in its 2020 earnings report, Amgen reported well over $1 billion in revenue from its bevacizumab (Mvasi, $798 million) and trastuzumab (Kanjinti, $567 million) biosimilars, along with $331 million in global revenue from its adalimumab biosimilar (Amgevita), which has become the most prescribed adalimumab biosimilar in Europe, with sales up 54% in 2020, according to Amgen.
Biosimilars are costly to develop and bring to market, and for that reason, they retail for significantly more than simple molecule generics. At the same time, discounts offered for the relatively few biosimilars on the market are significantly less than for generics, which affords biosimilar developers opportunity for enormous profit.
Roche’s 2020 results indicate that in the United States, Europe, Japan, and other countries, overall sales declines were 25% for Avastin, 31% for Rituxan/MabThera, and 34% for Herceptin.
Roche’s key revenue engines now comprise relatively new drugs, rather than bevacizumab, trastuzumab, and rituximab. At Roche, those latter products dipped from 40% of sales in 2019 to 29% of sales in 2020. The company’s new products category now represents 41% of sales vs 31% before. Overall, Roche was able to report a 1% increase in sales for the year.
The company identified Tecentriq (atezolizumab), Hemlibra (emicizumab), Ocrevus (ocrelizumab), and Actemra/RoActemra (tocilizumab) as several leading new products whose global sales advanced dramatically in 2020: 55%, 68%, 24%, and 32%, respectively.
Tocilizumab is for the treatment of rheumatoid arthritis; ocrelizumab, multiple sclerosis; emicizumab, haemophilia A; and atezolizumab, various forms of cancer.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.